Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Last trade$17.95
Day change-$1.02 (-5.38%)
Day range$17.75 – $19.70
Volume495,360
Market cap$1.17B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.17B
Price / earnings
0.86×
Price / book
-8.5×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.13×
Profitability
Earnings per share
$22.04
Return on assets
272.76%
Return on equity
-986.88%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
13.5×
Quick ratio
13.5×
Cash ratio
2.17×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$119.68M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VOR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$23.91M
$21.93M
$17.57M
$16.77M
$13.97M
$12.79M
$6.59M
$5.96M
Research and development
$34.53M
$25.92M
$17.6M
$19.19M
$14.14M
$261.5M
$26.7M
$25.35M
Total operating expenses
$58.44M
$47.85M
$35.16M
$35.96M
$28.11M
$274.28M
$33.29M
$31.31M
Operating income
-$58.44M
-$47.85M
-$35.16M
-$35.96M
-$28.11M
-$274.28M
-$33.29M
-$31.31M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$86.73M
-$62.81M
-$219.59M
$1.72B
-$812.68M
-$1.57B
-$32.49M
-$30.71M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$86.73M
-$62.81M
-$219.59M
$1.72B
-$812.68M
-$1.57B
-$32.49M
-$30.71M
Net income attributable to common shareholders
-$86.73M
-$62.81M
-$219.59M
$1.72B
-$812.68M
-$1.57B
-$32.49M
-$30.71M
EBITDA
-$58.41M
-$47.82M
-$35.13M
-$35.94M
-$28.11M
-$272.25M
-$32.47M
-$30.45M
Basic earnings per share
-$1.45
-$1.16
-$5.11
$84.87
-$121.63
-$251.24
-$5.21
-$8.77
Diluted earnings per share
-$1.45
-$1.16
-$5.11
$84.87
-$121.63
-$251.24
-$5.21
-$8.77
Recent news
Company coverage with links to the original publishers.
Vor Bio announced completion of enrollment in its Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis, with topline results expected in 1H27. The company expanded into ocular myasthenia gravis with a new Phase 3 trial and continues enrollment in primary Sjögren's disease. With $481.6 million in cash, the company projects runway into early 2029. Additional data from the TELIGAN trial showed telitacicept demonstrated durable kidney function preservation in IgA nephropathy.
Vor Bio announced the grant of stock options for 59,250 shares and RSUs for 12,550 shares to 9 newly hired employees on October 1, 2026, as material inducements to employment. The options have a 10-year term with an exercise price of $18.06 per share and vest over four years. The company continues advancing telitacicept through Phase 3 clinical development for autoimmune diseases, with enrollment completed in the UPSTREAM MG trial and expansion into ocular myasthenia gravis.
Vor Bio announced on July 1, 2026, that it granted stock options to purchase 71,200 shares and RSUs representing 15,150 shares to 7 newly hired employees as material inducements to employment. The options have a 10-year term with an exercise price of $18.39 per share and vest over four years, with RSUs vesting quarterly over the same period.
Vor Bio announced the grant of stock options to purchase 61,050 shares and RSUs representing 12,900 shares to 10 newly hired employees on June 1, 2026. The stock options have a 10-year term with an exercise price of $14.57 per share and vest over four years, with 25% vesting after 12 months followed by monthly vesting. The RSUs also vest over four years with similar terms but quarterly vesting for the remaining shares.
Vor Bio announced the grant of stock options to purchase 42,650 shares and RSUs representing 9,050 shares to 9 newly hired employees on April 1, 2026. The stock options have a 10-year term with an exercise price of $17.39 per share and vest over four years, with 25% vesting after 12 months followed by monthly vesting. The grants were made as material inducements to employment under the company's 2023 Inducement Plan.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.